| Grant number: | 20/02006-0 |
| Support Opportunities: | Research Grants - Research Partnership for Technological Innovation - PITE |
| Start date: | November 01, 2020 |
| End date: | April 30, 2023 |
| Field of knowledge: | Biological Sciences - Biochemistry - Chemistry of Macromolecules |
| Agreement: | Agilent |
| Principal Investigator: | Katlin Brauer Massirer |
| Grantee: | Katlin Brauer Massirer |
| Host Institution: | Centro de Biologia Molecular e Engenharia Genética (CBMEG). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil |
| Company: | Agilent Technologies Brasil Ltda |
| City: | CampinasBarueri |
| Associated researchers: | José Matheus Camargo Bonatto ; Opher Gileadi |
| Associated scholarship(s): | 21/04867-5 - Characterizatin of the interactome and mRNA-targets of the protein BICC1,
BP.MS 20/16094-8 - Structural charaterization of RNA binding proteins and fragment-based screening by Liquid Chromatography and mass spectrometry, BP.PD |
Abstract
With the aim of expanding the druggable proteome and lead to the discovery of new medicines, we work on the characterization of understudied human proteins, which show preliminary connection to disease. Within this aim, research has been expanded on the importance of protein related to RNA biology as antibody and drug targets, including the proteins 'per se' and their upstream modulators as kinases and methyltranferases. Thus, RNA binding proteins as well as kinase proteins constitute important biological targets for the advancement of biopharma. Those proteins can be targeted by small-molecule chemical probes, which are molecules defined as having high affinity and selectivity for a target and which can enter the cell to engage the target in vivo. Probes work as a complement to biological reagents for target validation and can be refined to become new drugs. In addition, biological targets can also lead to immunotherapy. In this project we aim to contribute for the characterization of the RNA binding protein BICC (Bicaudal C Homology 1) and UHMK (U2AF homology motif Serine/Threonine-Protein kinase) as potential drug targets related to cancer and neurological. We will characterize its interactors, target mRNAs and search for new chemical ligands. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |